CASI Reports H1 2026: $20M Loss, $3.8M Cash, Going Concern Warning
CASIF has more than doubled off its 52-week low of $0.05 on light trading volume (0.3× avg).
Summary
CASI Pharmaceuticals reported a $20 million first-half loss with only $3.8 million in cash and a going concern warning, confirming severe financial distress.
Key Events · Earnings and Guidance · CASIF
-
Going Concern Warning
The filing states that recurring operating losses have raised substantial doubt regarding the company's ability to continue as a going concern.
-
H1 2026 Financial Results
Revenue declined 5.8% to $9.8 million; net loss was $20.0 million, improved from $24.1 million a year earlier.
-
Cash Position Deteriorating
Cash and cash equivalents fell to $3.8 million as of June 30, 2026, down from $5.6 million at year-end 2025.
-
Nasdaq Delisting Completed
Nasdaq filed Form 25 on June 23, 2026, completing the delisting; shares now trade on OTCQB under CASIF.
Analysis · CASIF · Life Sciences
CASI Pharmaceuticals disclosed first-half 2026 results showing a $20.0 million net loss and only $3.8 million in cash as of June 30, 2026. The filing explicitly states that recurring operating losses have raised substantial doubt about the company's ability to continue as a going concern. This is a critical liquidity warning for a company with a market cap of roughly $3 million. The company also confirmed its Nasdaq delisting was completed in June 2026, with shares now trading on OTCQB. While the company reported progress on its CID-103 clinical program, the financial position is precarious: current liabilities of $66.6 million dwarf total assets of $21.1 million, and shareholders' deficit widened to $58.3 million. The $15 million convertible note financing from a related party provides some runway but adds to the debt burden. This filing materially changes the investment thesis by quantifying the severity of the company's financial distress.
At the time of this filing, CASIF was trading at $0.15 on OTC in the Life Sciences sector, with a market capitalization of approximately $3M. The 52-week trading range was $0.05 to $3.09. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.